Business Context and Reporting Period
The Ensign Group, Inc. (ENSG) is a holding company operating independent subsidiaries that provide post-acute care services, including skilled nursing, senior living, and rehabilitation therapy. As of September 30, 2024, the company operated 322 facilities with approximately 33,000 skilled nursing beds and 3,100 senior living units across 14 states. The company also owns a captive REIT, Standard Bearer Healthcare REIT, Inc., which manages its real estate portfolio. This filing covers the quarterly period ended September 30, 2024.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $1,081.8 million | $940.8 million | $3,128.2 million | $2,749.0 million |
| Net Income (Attributable to Ensign) | $78.4 million | $63.9 million | $218.3 million | $187.7 million |
| Diluted EPS | $1.34 | $1.11 | $3.76 | $3.28 |
| Operating Income | $89.3 million | $79.8 million | $257.5 million | $232.5 million |
| Operating Margin | 8.3% | 8.5% | 8.3% | 8.5% |
| Cash from Operations (9M) | $246.7 million | $291.4 million | $246.7 million | $291.4 million |
| Cash and Equivalents (End of Period) | $532.1 million | $467.9 million | $532.1 million | $467.9 million |
| Total Debt (Long-term + Current) | $146.6 million | $149.4 million | $146.6 million | $149.4 million |
Liquidity: The company maintains a $600 million revolving credit facility with no outstanding borrowings as of September 30, 2024. Cash and cash equivalents increased to $532.1 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 15.0% in Q3 2024 and 13.8% for the nine months ended September 30, 2024, compared to the prior year periods. This growth was driven by a 2.0% increase in consolidated occupancy (80.9% in Q3 2024 vs. 78.9% in Q3 2023) and the addition of 26 new operations during the nine-month period.
- Profitability: Net income attributable to the company increased 22.8% in Q3 2024 and 16.3% for the nine-month period. Diluted EPS grew 20.7% in Q3 2024.
- Operating Expenses: Cost of services increased 15.5% in Q3 2024, primarily due to new acquisitions in the turnaround stage, increased healthcare costs, and higher liability reserves. Cost of services as a percentage of revenue rose slightly to 79.8% in Q3 2024 from 79.0% in Q3 2023.
- Cash Flow: Net cash provided by operating activities decreased $44.7 million for the nine months ended September 30, 2024, compared to the prior year. This decrease was primarily due to the timing of income tax payments ($82.0 million paid in 2024 vs. $8.5 million in 2023), as 2023 payments were deferred due to disaster-area tax relief.
- Investing Activities: Cash used in investing activities increased significantly to $223.5 million for the nine months ended September 30, 2024, from $137.8 million in the prior year, driven by operational expansions and capital expenditures of $110.1 million.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects to continue expanding operations and improving occupancy and skilled mix at acquired facilities. The company anticipates that existing cash, operating cash flows, and available financing will support operations for the next 12 months.
- Regulatory Risks: The company faces significant regulatory scrutiny, including a Civil Investigative Demand (CID) from the U.S. Department of Justice regarding Medicare and Texas Medicaid claims. Additionally, the company is subject to the CMS "Staffing Rule" establishing minimum staffing standards, which may increase labor costs. The company is also subject to the "SNF 5-Claim Probe & Educate Review" nationwide audit.
- Legal Proceedings: The company settled a qui tam civil case in January 2024 for approximately $48.0 million, subject to DOJ review. The settlement does not include an admission of wrongdoing. The company is also appealing a medical negligence verdict from late 2023.
- Unusual Items: The company recorded a $1.8 million impairment charge on long-lived assets during the nine months ended September 30, 2024. Stock-based compensation expense increased to $26.4 million for the nine months ended September 30, 2024, from $22.7 million in the prior year.
- Dividends: The company declared dividends of $0.06 per share in each of the first three quarters of 2024.
Investor Verification Checklist
- Verify the impact of the $48.0 million qui tam settlement on future cash flows and legal reserves.
- Monitor the outcome of the DOJ Civil Investigative Demand (CID) regarding Medicare and Texas Medicaid claims.
- Assess the financial impact of the new CMS minimum staffing mandates on labor costs and margins.
- Review the integration progress and occupancy trends of the 26 new facilities acquired in the first nine months of 2024.
- Confirm the company's compliance with debt covenants, specifically the maximum consolidated total net debt to consolidated EBITDA ratio (3.75:1.00).
- Track the timing of future income tax payments to understand cash flow volatility.